Kisspeptin Side Effects: What Five Trial Records Logged, and Why Daily Use Switches the Hormone Off

Kisspeptin is the hormone that switches on the reproductive axis: it acts on GnRH neurons, which release LH and FSH, which drive testosterone and oestrogen. It has been given to people for twenty years in academic research — mostly at Imperial College London and Massachusetts General Hospital — but it has never been approved as a medicine, so there is no label and no table of rates. What exists is a set of trial records, a few of which posted their adverse events on ClinicalTrials.gov. This page reads those records, adds the one finding that matters more than any listed symptom, and states what has not been studied. Doses and units are on our kisspeptin dosage page; how it compares with the hormone it is most often stacked against is on our hCG vs kisspeptin page.

Where the record comes from

A ClinicalTrials.gov query for kisspeptin as an intervention returned 36 studies on 2026-10-09. Many are observational — they measure kisspeptin in blood rather than give it — and most interventional ones gave one dose, or a few hours of infusion, under supervision. Five registered studies have posted results, and their adverse-event tables are the closest thing kisspeptin has to a label. They are small, and none ran longer than about three months.

The last two used Takeda's analogue TAK-448, not native kisspeptin. Their tables are worth reading for one reason: in the low-testosterone study, four of the five men on placebo logged an event too, against seven of the twelve on the drug. In studies this small, a list of symptoms is mostly a list of what happens to people over eight weeks.

The symptoms that were logged

The hyperprolactinaemia study is the most useful, because it gave native kisspeptin by both routes and posted every event:

Taken together, headache appears in 7 of 36 people (19%) — the most frequent event in any posted kisspeptin table. There was no placebo arm, so the share that kisspeptin caused cannot be separated out. The pulsatile study adds fatigue (2 of 18), hot flushes, a skin infection, dizziness and breathlessness (1 each), plus the one serious event on the registry for native kisspeptin: rhabdomyolysis, which the record places after completion of the study visits. The registry does not say whether investigators judged it related.

Several published single-dose trials report nothing at all. The 2022 study in 40 women with low sexual desire describes kisspeptin as "well-tolerated with no reported adverse effects" (PMID 36287566), and the 2025 nasal-spray study reports no side effects or adverse events in healthy men, women and patients with hypothalamic amenorrhoea (PMID 40215751). Those statements cover an hour or two of exposure in a research unit.

The IVF trial: what its serious events were

The largest registered kisspeptin study gave kisspeptin-54 to 175 women as the trigger for egg maturation in IVF, including a group at high risk of ovarian hyperstimulation syndrome (OHSS), the complication the standard hCG trigger can provoke. In the 60 high-risk women reported in 2015, no woman developed moderate, severe or critical OHSS (PMID 26192876).

Every serious event the trial posted was a pregnancy outcome: by our count of its table, 6 ectopic pregnancies, 6 miscarriages, 1 heterotopic pregnancy and 1 stillbirth across the 175. Those are events IVF pregnancies carry whatever the trigger, and the record does not attribute them to kisspeptin; there was no non-kisspeptin comparison group to measure against. They are reported here because they are what the registry lists, and because "serious adverse events" on a fertility trial means something different from the same words on a drug trial in men.

The finding that matters most: repeated dosing switches the response off

The side effect of kisspeptin best supported by evidence is not a symptom. It is that continuous or frequent exposure stops it working, and can reverse its effect.

The last row is the clearest. Takeda developed TAK-448 as a testosterone-suppressing drug for prostate cancer, because continuous kisspeptin-receptor stimulation desensitises the axis the way continuous GnRH-agonist exposure does. In 82 healthy men the analogue was "well tolerated", with grade 1–2 adverse events in 26%, and depot injections drove testosterone below 20 ng/dL in four of five men with prostate cancer. Native kisspeptin is far shorter-lived than TAK-448, but the receptor biology is the same, and the 2009 and 2026 studies show it with the native hormone.

This is why the human literature is careful about timing, and why the questions research-market buyers ask — "can kisspeptin raise testosterone?", "can I use it every day?" — do not have one answer. In the trials, intermittent exposure raised hormones and continuous exposure flattened or suppressed them.

What the record does not contain

• No approved label, no rates from a large population. The largest study with posted results enrolled 175; most enrolled under 40, and the one registered study of 256 adults (NCT00914823) has posted no results.
• No exposure beyond about three months, and almost none beyond two weeks of daily use.
• No study of the products sold as research chemicals, which are not the GMP peptide the trials used — see what research-use-only labelling means.
• Almost nothing in FDA's adverse-event database. An openFDA query on 2026-10-09 (data updated 2026-07-30) returned one report naming kisspeptin. For an unapproved compound, that reflects how little is reported; our peptide side-effects overview explains why near-zero counts prove nothing.
• No study in people with hormone-sensitive conditions, which is exactly where an agent that raises sex hormones would need one.

Anyone weighing kisspeptin, or connecting a symptom to it, should take the question to an endocrinologist or a fertility specialist; the registry records above are the documents to bring. Peptide Lexicon's kisspeptin entry covers what the hormone is and where it comes from.

Sources and dates

• ClinicalTrials.gov API v2, intervention "kisspeptin": 36 studies, queried 2026-10-09. Adverse-event modules read for NCT02956447, NCT04648969, NCT01667406, NCT02381288 and NCT02369796 on the same date.
• Jayasena CN et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-23. PMID 19820030.
• Jayasena CN et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea. Clin Pharmacol Ther. 2010. PMID 20980998.
• Yeung AC et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026;195(2):206-216. PMID 42549827.
• MacLean DB et al. Sustained exposure to the investigational kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer. J Clin Endocrinol Metab. 2014;99(8):E1445-53. PMID 24762108.
• Abbara A et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy. J Clin Endocrinol Metab. 2015. PMID 26192876.
• Thurston L et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder. JAMA Netw Open. 2022. PMID 36287566.
• Mills EG et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025. PMID 40215751.
• openFDA drug adverse event endpoint, medicinal product "kisspeptin": 1 report, queried 2026-10-09 (dataset updated 2026-07-30).